You are here: HNCU 1 | 2007: Marshall R Posner, MD - Select Publications

Bonner JA et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78. Abstract

Brizel DM et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798-804. Abstract

Calais G et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Proc ASCO 2006;Abstract 5506.

Cooper JS et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937-44. Abstract

Kim ES et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. Proc ASCO 2007;Abstract 6013.

Posner MR et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15. Abstract

Vermorken J et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy — Results of a randomized phase III (Extreme) study. Proc ASCO 2007a; Abstract 6091.

Vermorken JB et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007b;357(17):1695-704. Abstract